title: [Aquaretic drugs--a new therapeutic principle in treatment of hyponatremia?].
abstract: The antidiuretic hormone (vasopressin) is involved, either directly or indirectly, in the pathogenesis of almost all forms of hyponatremia. This means that blockage of the ADH effect at the renal ADH receptor represents a rational approach in the treatment of hyponatremia, in particular in difficult-to-treat and symptomatic forms. Recently, orally absorbable, non-peptidergic competitive ADH antagonists (aquaretics) have been introduced, which bind with high affinity to renal ADH receptor subtypes. Initial investigations in humans show that the substance is well tolerated. Numerous studies on patients with hyponatremia of varying genesis have since been started. It is to be expected that the availability of this new dass of substances will result in marked improvements in the treatment of acute and chronic forms of hyponatremia.
authors.affiliation: Abt. Endokrinologie, Univ. Erlangen-Nürnberg.
authors.forename: J
authors.initials: J
authors.lastname: Hensen
authors.forename: M
authors.initials: M
authors.lastname: Buchfelder
authors.forename: P
authors.initials: P
authors.lastname: Gross
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy* / Q000209:etiology; D007177:Inappropriate ADH Syndrome / Q000188:drug therapy* / Q000209:etiology; D007668:Kidney / Q000187:drug effects; D008297:Male; D014667:Vasopressins / Q000037:antagonists & inhibitors*
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D014667:Vasopressins; C076251:mozavaptan